Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.
Status:
Withdrawn
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine whether intralesional cidofovir is effective at
bringing about the total or near-total resolution of warts that have already proven
recalcitrant to standard therapy.
The secondary objective is to determine the tolerability of this new mode of administration
of cidofovir in the pediatric population
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute